Literature DB >> 21558454

Counterpoint: Both immunohistochemistry and fluorescence in situ hybridization play important roles for HER2 evaluation.

Kenneth J Bloom1, Richard J Cote.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21558454     DOI： 10.1373/clinchem.2010.160853

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


× No keyword cloud information.
  2 in total

1.  The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma.

Authors:  Eleonora Brunello; Giuseppe Bogina; Emilio Bria; Marco Vergine; Giuseppe Zamboni; Serena Pedron; Isabella Daniele; Jenny Furlanetto; Luisa Carbognin; Marcella Marconi; Erminia Manfrin; Merdol Ibrahim; Keith Miller; Giampaolo Tortora; Annamaria Molino; Bharat Jasani; Serena Beccari; Franco Bonetti; Marco Chilosi; Guido Martignoni; Matteo Brunelli
Journal:  J Cancer Res Clin Oncol       Date:  2013-07-28       Impact factor: 4.553

2.  FISH testing of HER2 immunohistochemistry 1+ invasive breast cancer with unfavorable characteristics.

Authors:  Stella Petroni; Lucia Caldarola; Rachele Scamarcio; Francesco Giotta; Agnese Latorre; Anita Mangia; Giovanni Simone
Journal:  Oncol Lett       Date:  2016-09-13       Impact factor: 2.967
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.